Close Menu

NEW YORK – Inivata said on Thursday that it has partnered with Maverick Therapeutics to use Inivata's Radar (Residual Disease and Recurrence) assay to detect and monitor residual disease and recurrence in patients enrolled in Maverick's Phase I/II clinical study for its MVC-101 drug candidate.

As part of the study, the team will use Radar to monitor circulating tumor DNA from multiple tumor types in trial participants following MVC-101 treatment.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.